PropertyValue
?:abstract
  • Background: We developed a heterologous COVID-19 vaccine consisting of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-S and rAd5-S) We aimed to assess the safety and immunogenicity of two formulations (frozen and lyophilised) of this vaccine
is ?:annotates of
?:creator
?:journal
  • Lancet
?:license
  • unk
?:publication_isRelatedTo_Disease
?:source
  • WHO
?:title
  • Safety and immunogenicity of an rad26 and rad5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
?:type
?:who_covidence_id
  • #974769
?:year
  • 2020

Metadata

Anon_0  
expand all